A New Chapter in the ATTR Story: From Nihilism to Optimism

Statement of Need

Transthyretin amyloidosis (ATTR), including hereditary variants such as ATTRv-CM and ATTRv-PN, remains underdiagnosed despite increased awareness and treatment advances. Many patients experience significant diagnostic delays, often seeing multiple clinicians before receiving a correct diagnosis, which can limit treatment efficacy and worsen outcomes. ATTR’s diverse presentations, overlapping symptoms with more common conditions, and limited access to diagnostic tools—especially genetic testing and advanced imaging—compound these challenges. While transformative therapies including gene silencers and TTR stabilizers have shifted treatment from palliative care to disease modification, clinicians struggle to stay abreast of evolving evidence and integrate these innovations into individualized treatment plans. Additionally, gaps remain in implementing multidisciplinary team (MDT) models, critical for coordinated care in this multisystem disease.

This activity, presented by experts in cardiology, neurology, and advanced practice care, will better equip clinicians to implement best practices in diagnosis, therapeutic strategy, and MDT collaboration to improve clinical outcomes for patients with ATTRv.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Utilize appropriate diagnostic tools and techniques to identify ATTRv-CM and ATTRv-PN, including genetic testing, imaging modalities, and tissue biopsy
Develop personalized, contemporary treatment plans for patients with ATTRv-CM and ATTRv-PN based on rapidly evolving clinical evidence
Identify opportunities for MDT collaboration to enhance patient care outcomes in ATTRv

Financial Support

This program has been supported by an independent educational grant from Alnylam Pharmaceuticals, Inc.

Target Audience

Neurologists, cardiologists, neuromuscular-peripheral neuropathy specialists, geneticists, PCPs, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 0.75

CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 0.75

This application-based activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy credit (JA0007185-0000-25-056-H01-P).

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 0.75 Contact Hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Interprofessional (IPCE) 0.75

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA): 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 06/30/2026. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.75

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Joshi reports no financial relationships to disclose.

Dr. Karam reports the following financial relationships:

Advisory Board and Consultant: Alexion; Alnylam Pharmaceuticals, Inc.; Alpine Pharmaceuticals; Amgen Inc.; Amicus Therapeutics, Inc.; Annexon, Inc; argenx; AstraZeneca; Biogen; Corino Therapeutics, Inc.; CSL Behring; Genentech, Inc.; Ionis Pharmaceuticals; Johnson & Johnson; NeuroDerm; Novo Nordisk; Octapharma USA, Inc.; Pfizer Inc.; Sanofi; UCB, Inc.; Takeda Pharmaceutical Company; and Zai lab

Grants: argenx; Ionis Pharmaceuticals; and Sanofi/Genzyme

Dr. Witteles reports the following financial relationships:

Consultant: Alexion; Alnylam Pharmaceuticals, Inc.; AstraZeneca; BridgeBio Pharma, Inc.; Novo Nordisk; and Pfizer Inc.

Research Support: Alexion; Alynylam Pharmaceuticals, Inc.; Eidos Therapeutics, Inc./BridgeBio Pharma; Intellia Therapeutics, Inc.; Ionis Pharmaceuticals; and Janssen Pharmaceuticals, Inc.

The following individuals have no financial relationships to disclose:

Thai Nguyen, MD, MHA (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Thomas Mitchell, MSW (Planning Committee)
Warren Beckman (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-267-063025-77